Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Septal Defect Clear all
Not listed Phase 2Phase 3 Interventional

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

NCT00283738
View directory record Official record
Conditions
Migraine, Aura, Patent Foramen Ovale
Interventions
BioSTAR Septal Repair Implant System, Sham Procedure
Device · Procedure
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Stamford, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jul 21, 2026, 9:54 PM EDT
Not yet recruiting Not applicable Interventional

Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?

NCT07393243
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
Clear priming of the bypass pump
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 21, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Optical Tissue Identification for Myocardial Architecture

NCT04017975
View directory record Official record
Conditions
Ventricular Septal Defect, Complete Atrioventricular Canal, Tetralogy of Fallot With Pulmonary Stenosis
Interventions
Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes
Drug · Device
Lead sponsor
Aditya Kaza
Other
Eligibility
30 Days to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study

NCT00650936
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
AMPLATZER Septal Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jul 21, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional

Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

NCT00113698
View directory record Official record
Conditions
Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive
Interventions
Enalapril, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics

NCT01915277
View directory record Official record
Conditions
Transposition of the Great Arteries, Tetralogy of Fallot, Ventricular Septal Defect
Interventions
Dexmedetomidine
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 180 Days
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 21, 2026, 9:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Energy Expenditure in Infants With Ventricular Septal Defects

NCT00006272
View directory record Official record
Conditions
Heart Septal Defects, Ventricular
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Months to 4 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1994
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 9:54 PM EDT
Completed No phase listed Observational Results available

Philips Intracardiac Echocardiography (ICE) Clinical Registry

NCT04950192
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions
ICE Image guidance
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Jul 21, 2026, 9:54 PM EDT
Active, not recruiting Not applicable Interventional

AMPLATZER PFO Occluder Post Approval Study

NCT03309332
View directory record Official record
Conditions
Stroke, Patent Foramen Ovale
Interventions
AMPLATZER™ PFO Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

NCT03945643
View directory record Official record
Conditions
Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease

NCT00480740
View directory record Official record
Conditions
Cardiac Transplant, Patent Ductus Arterious, Atrial Septal Defect, Bidirectional Cavopulmonary Anastomosis
Interventions
Dexmedetomidine
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 21, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 9:54 PM EDT
Withdrawn Phase 2 Interventional

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

NCT02378623
View directory record Official record
Conditions
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder

NCT00583791
View directory record Official record
Conditions
Heart Septal Defects, Ventricular
Interventions
Device closure with the AMPLATZER Muscular VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Denver, Colorado • Orlando, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Jul 21, 2026, 9:54 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of Atrial Septal Defects

NCT00498446
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt

NCT04604015
View directory record Official record
Conditions
Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Right-To-Left Atrial Shunt, Patent Foramen Ovale
Interventions
NeuralBot Investigational System, Transthoracic Echocardiography (TTE)
Diagnostic Test
Lead sponsor
NovaSignal Corp.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Phoenix, Arizona • Portland, Oregon • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER

NCT00578708
View directory record Official record
Conditions
Membranous Ventricular Septal Defects
Interventions
AMPLATZER Membranous VSD Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jul 21, 2026, 9:54 PM EDT
Not listed Not applicable Interventional

Does Patent Foramen Ovale Closure Improve Exercise Capacity & Prevent Blood Flow Through Intrapulmonary Shunt

NCT03904290
View directory record Official record
Conditions
Patent Foramen Ovale
Interventions
PFO Closure
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 21, 2026, 9:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

NCT04100135
View directory record Official record
Conditions
Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
Interventions
Actual device PFO closure, Thienopyridine (clopidogrel or prasugrel), Sham device PFO closure
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Barbara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Use of Ketamine Prior to Cardiopulmonary Bypass in Children

NCT00556361
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
saline, ketamine
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Jul 21, 2026, 9:54 PM EDT
Terminated No phase listed Observational

Optimal Timing for Repair of Left to Right Shunt Lesions

NCT00229827
View directory record Official record
Conditions
Ventricular Septal Defects, Persistent Common Atrioventricular Canal
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jul 21, 2026, 9:54 PM EDT
Not listed Phase 2Phase 3 Interventional

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

NCT00201461
View directory record Official record
Conditions
Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions
STARFlex septal closure system, Best medical therapy
Device · Drug
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

NCT00738894
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Septal Occluder Device, Antiplatelet Medical Therapy
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 60 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jul 21, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Results available

Utilization of Confocal Microscopy During Cardiac Surgery

NCT03189134
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes
Drug · Device
Lead sponsor
Aditya Kaza
Other
Eligibility
30 Days to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 21, 2026, 9:54 PM EDT